Orthocell has applied to the Therapeutic Good Administration (TGA) for Australian market approval for its SmrtGraftâ„¢ tendon repair device, in preparation for its introduction into the Australian tendon repair and regeneration market.
Remplirâ„¢ nerve repair study published in peer-reviewed clinical journal
Orthocell has announced that results from the Remplirâ„¢ nerve regeneration clinical trial have been published in a high profile clinical journal.
Orthocell receives $3.05m R&D tax incentive refund
Orthocell has announced that it has received a Research and Development (R&D) Tax Incentive refund of A$3,051,483 for the financial year 2022/2023.
Quarterly Report – Period To 31 March 2024
Orthocell has today published its Quarterly Report for the period ended 31 March 2024.
Proactive Interview with Paul Anderson
Orthocell Managing Director, Paul Anderson, spoke with Jonathan Jackson at Proactive to provide an update on the Company’s market authorisation study for nerve repair device, Remplirâ„¢.
Orthocell Successfully Completes Surgeries for Remplirâ„¢ US Market Authorisation
Orthocell has announced that it has successfully completed the first stage of the Remplirâ„¢ US 510(k) market authorisation nerve repair study.
Proactive | Interview with CEO Paul Anderson
Orthocell CEO Paul Anderson spoke with Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.
The West Australian | Chris Ellison, Rod Jones and the McCuskers jump into Orthocell
Orthocell’s Company-led strategic placement has been reported in The West Australian newspaper today, in an article by Senior Business Report Sean Smith titled “Chris Ellison, Rod Jones and the McCuskers jump into Orthocell”.
Orthocell Completes $3.5M Strategic Placement
Orthocell has today announced that it has completed a Company-led Strategic Placement to raise $3.5 million.
Orthocell submits Singapore Regulatory Application for Remplirâ„¢
Orthocell has today announced that the Company has submitted a regulatory application to the Health Services Authority of Singapore for approval to market and sell Remplirâ„¢ for use in peripheral nerve repair procedures